GE Healthcare Technologies Inc's stock plummeted 11.55% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results.

The sharp decline was triggered by the company reporting an adjusted earnings per share of $0.99, which missed the IBES estimate of $1.05. Despite revenue of $5.10 billion exceeding expectations, investors reacted negatively to the earnings shortfall and a significant reduction in the company's full-year profit outlook. GE Healthcare cut its 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from its prior forecast of $4.95 to $5.15 and below the market consensus of approximately $5.06.

Management cited a substantially changed inflation landscape, with significant increases in memory chips, oil, and freight costs during the quarter that are expected to impact results for the remainder of 2026, increasing expected input costs by about $250 million. Profitability in the quarter was also affected by a discrete supplier issue in its pharmaceutical diagnostics business, which has since been resolved. The company stated it is reducing its profit outlook but expects to offset more than half of the inflation impact through price adjustments and cost-saving actions.